| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786215 | Clinical Oncology | 2018 | 8 Pages |
Abstract
Focal rSBRT can achieve durable remission in locally relapsing patients and systemic treatment can be postponed with acceptable toxicity. Accurate patient selection is mandatory to maximise disease control.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Loi, V. Di Cataldo, G. Simontacchi, B. Detti, P. Bonomo, L. Masi, I. Desideri, D. Greto, G. Francolini, V. Carfora, D. Pezzulla, M. Perna, G.A. Carta, L. Livi,